Payment overview · 2025
General Payments
$758.14
34 reported records · 14 companies
Healthcare provider profile · identity verified
Benjamin Scott Dieter, MD
Allopathic & Osteopathic Physicians|Family Medicine · HENDERSON, NC · NPI 1538352968
Verified facts
What the public records show
CMS Open Payments records show Benjamin Scott Dieter, MD received $758.14 in general payments during 2025 across 34 reported records.
Novo Nordisk Inc accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $185.70 | 24.5% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $151.80 | 20.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.83 | 19.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $66.01 | 8.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.16 | 4.4% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $24.88 | 3.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.13 | 2.9% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $21.46 | 2.8% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $20.57 | 2.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.55 | 2.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.18 | 2.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.12 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.88 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.87 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $758.14 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $150.83 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $150.83 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $150.83 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $132.48 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $101.40 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.79 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $80.79 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.52 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $66.01 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.08 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 171 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 172 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
172 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
171 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 605 | 151 |
| Omeprazole | Omeprazole | 539 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 422 | 122 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 345 | 93 |
| Gabapentin | Gabapentin | 318 | 63 |
| Lisinopril | Lisinopril | 301 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 264 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 255 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 51 |
| Furosemide | Furosemide | 184 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 174 | 54 |
| Ozempic | Semaglutide | 172 | 26 |
| Eliquis | Apixaban | 171 | 34 |
| Losartan Potassium | Losartan Potassium | 163 | 51 |
| Metformin Hcl Er | Metformin Hcl | 155 | 44 |
| Carvedilol | Carvedilol | 135 | 36 |
| Allopurinol | Allopurinol | 134 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 34 |
| Mirtazapine | Mirtazapine | 132 | 32 |
| Metformin Hcl | Metformin Hcl | 125 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 30 |
| Simvastatin | Simvastatin | 118 | 31 |
| Chlorthalidone | Chlorthalidone | 117 | 35 |
| Alendronate Sodium | Alendronate Sodium | 115 | 31 |
| Spironolactone | Spironolactone | 114 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 35 |
| Potassium Chloride | Potassium Chloride | 108 | 29 |
| Trazodone Hcl | Trazodone Hcl | 101 | 26 |
| Jardiance | Empagliflozin | 99 | 22 |
| Montelukast Sodium | Montelukast Sodium | 99 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 30 |
| Valsartan | Valsartan | 97 | 25 |
| Sertraline Hcl | Sertraline Hcl | 96 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 28 |
| Pregabalin | Pregabalin | 84 | 20 |
| Celecoxib | Celecoxib | 76 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 24 |
| Ondansetron Odt | Ondansetron | 66 | 13 |
| Ezetimibe | Ezetimibe | 65 | 16 |
| Glipizide Er | Glipizide | 65 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 14 |
| Farxiga | Dapagliflozin Propanediol | 59 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 55 | 15 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Prednisone | Prednisone | 51 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 13 |
| Mounjaro | Tirzepatide | 50 | 15 |
| Torsemide | Torsemide | 50 | 14 |
| Benazepril Hcl | Benazepril Hcl | 49 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 22 |
| Topiramate | Topiramate | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 21 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 13 |
| Baclofen | Baclofen | 45 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | suppressed |
| Glimepiride | Glimepiride | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Lorazepam | Lorazepam | 43 | 21 |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 11 |
| Fluconazole | Fluconazole | 40 | 24 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Linzess | Linaclotide | 39 | 11 |
| Naproxen | Naproxen | 38 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 37 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Meloxicam | Meloxicam | 29 | 14 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Novolog | Insulin Aspart | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Colchicine | Colchicine | 21 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 17 |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | 11 |
| Glipizide | Glipizide | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 14 |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 13 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Topiramate Er | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $758.14 · 34 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, APRETUDE, BREZTRI, CAPLYTA, COMIRNATY, CeQur Simplicity, ELIQUIS, FARXIGA, Korlym, NEXPLANON, NURTEC ODT, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, UZEDY, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error